01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan #ORPH – Major New Contract Win for Venn Life Sciences June 11, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH) a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce that it has signed a major contract with a leading vaccine developer and one of the top pharmaceutical companies in the world. The contract with Venn Life Sciences, which is part of Open Orphan, builds on earlier successful contracts between the companies…

Continue reading

Open Orphan #ORPH – Interim Results for 6 months ended 30 June 2019 September 25, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focused, rare and orphan drug consulting services platform, announces its interim results for the six months ended 30 June 2019. Financial Highlights below (and in note 3 of the reported financial statements) reflect the interim results of Venn Life Sciences (“Venn”) prior to the reverse takeover by Open Orphan on the 28 June 2019. Reported results, based on IFRS accounting rules, reflect those of Open Orphan DAC while the Balance Sheet as of…

Continue reading

Open Orphan (ORPH) – Investor Event Attendance and Presentation September 3, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan presents at Shares Investor Evening, London Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at the Shares Investor Evening tomorrow from 18:00 at Novotel Hotel Tower Bridge, London, EC3N 2NR. Cathal Friel, Open Orphan’s Chief Executive Officer will be presenting from 18:30 onwards to update existing and potential investors on the Company’s business plans for 2019-2020. The event will provide an opportunity for…

Continue reading